Alzheimer's disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core

Biophysical Journal

Volumn 100, Issue 4, 2011, Pages 1076-1082

  Li, Jie ^a   Liu, Ruiwu ^c   Lam, Kit S ^c   Jin, Lee Way ^d   Duan, Yong ^a,b  

^a Genome Center   (United States)

^b Department of Applied Science ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951815645     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2010.12.3741     Document Type: Article

References (48)

1. Dobson, C. M. 1999. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:329-332. (Pubitemid 29421804)
2. Dobson, C. M. 2001. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:133-145. (Pubitemid 32241461)
3. Rochet, J. C., and P. T. Lansbury, Jr. 2000. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:60-68. (Pubitemid 30099328)
4. Wang, R., D. Sweeney, S. S. Sisodia. 1996. The profile of soluble amyloid β protein in cultured cell media. Detection and quantification of amyloid β protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 271:31894-31902. (Pubitemid 26422211)
5. Lührs, T., C. Ritter, R. Riek. 2005. 3D structure of Alzheimer's amyloid-β (1-42) fibrils. Proc. Natl. Acad. Sci. USA. 102:17342-17347. (Pubitemid 41740868)
6. Roberson, E. D., and L. Mucke. 2006. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 314:781-784. (Pubitemid 44706637)
7. Wang, D. S., D. W. Dickson, and J. S. Malter. 2006. β-Amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol. 2006:58406.
8. Crowther, D. C., K. J. Kinghorn, D. A. Lomas. 2005. Intraneuronal A β, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 132:123-135. (Pubitemid 40380720)
9. Cataldo, A. M., S. Petanceska, R. A. Nixon. 2004. Ab localization in abnormal endosomes: association with earliest Ab elevations in AD and Down syndrome. Neurobiol. Aging. 25:1263-1272. (Pubitemid 39299162)
10. Ikeuchi, T., G. Dolios, S. S. Sisodia. 2003. Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Aβ 1-40 and Aβ 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "γ-secretase". J. Biol. Chem. 278:7010-7018. (Pubitemid 36800696)
11. De Jonghe, C., C. Zehr, C. B. Eckman. 1998. Flemish and Dutch mutations in amyloid β precursor protein have different effects on amyloid β secretion. Neurobiol. Dis. 5:281-286. (Pubitemid 28519158)
12. Tomita, T., S. Tokuhiro, T. Iwatsubo. 1998. Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid β peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Aβ42. J. Biol. Chem. 273:21153-21160. (Pubitemid 28385404)
13. Johnson-Wood, K., M. Lee, L. McConlogue. 1997. Amyloid precursor protein processing and A β (42) deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1550-1555.
14. Teller, J. K., C. Russo, P. Gambetti. 1996. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2:93-95.
15. Lesné, S., M. T. Koh, K. H. Ashe. 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 440:352-357.
16. Walsh, D. M., M. Townsend, D. J. Selkoe. 2005. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci. 25:2455-2462. (Pubitemid 40365155)
17. Liao, M. Q., Y. J. Tzeng, Y. C. Chen. 2007. The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Aβ peptides. FEBS Lett. 581:1161-1165. (Pubitemid 46394550)
18. Zagorski, M. G., H. Shao, M. Papolla. 2000. Amyloid AB (1-40) and AB (1-42) adopt remarkably stable, monomeric, and extended structures in water solution at neutral pH. Neurobiol. Aging. 21: S10-S11.
19. Barrow, C. J., A. Yasuda, M. G. Zagorski. 1992. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J. Mol. Biol. 225:1075-1093.
20. Coles, M., W. Bicknell, D. J. Craik. 1998. Solution structure of amyloid β-peptide (1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry. 37:11064-11077. (Pubitemid 28368933)
21. Kirkitadze, M. D., M. M. Condron, and D. B. Teplow. 2001. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312:1103-1119. (Pubitemid 32980329)
22. Jarrett, J. T., E. P. Berger, and P. T. Lansbury. 1993. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation implications for the pathogenesis of Alzheimers disease. Biochemistry. 32:4693-4697. (Pubitemid 23162022)
23. Jarrett, J. T., E. P. Berger, and P. T. Lansbury, Jr. 1993. The C-terminus of the β protein is critical in amyloidogenesis. Ann. N. Y. Acad. Sci. 695:144-148.
24. Baumketner, A., and J. E. Shea. 2007. The structure of the Alzheimer amyloid β 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent. J. Mol. Biol. 366:275-285. (Pubitemid 46123329)
25. Tarus, B., J. E. Straub, and D. Thirumalai. 2006. Dynamics of Asp23-Lys28 salt-bridge formation in Aβ10-35 monomers. J. Am. Chem. Soc. 128:16159-16168. (Pubitemid 44936609)
26. Hamodrakas, S. J., C. Liappa, and V. A. Iconomidou. 2007. Consensus prediction of amyloidogenic determinants in amyloid fibril-forming proteins. Int. J. Biol. Macromol. 41:295-300. (Pubitemid 46990531)
27. Porat, Y., A. Abramowitz, and E. Gazit. 2006. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67:27-37. (Pubitemid 43881385)
28. Okuno, H., K. Mori, H. Suzuki. 2007. Development of aggregation inhibitors for amyloid-β peptides and their evaluation by quartz-crystal microbalance. Chem. Biol. Drug Des. 69:356-361. (Pubitemid 46817453)
29. Soldi, G., G. Plakoutsi, F. Chiti. 2006. Stabilization of a native protein mediated by ligand binding inhibits amyloid formation independently of the aggregation pathway. J. Med. Chem. 49:6057-6064. (Pubitemid 44484949)
30. Lee, K. H., B. H. Shin, J. Yu. 2005. A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by β-amyloid (1-42). Biochem. Biophys. Res. Commun. 328:816-823. (Pubitemid 40238712)
31. Nerelius, C., A. Sandegren, J. Johansson. 2009. α-Helix targeting reduces amyloid-β peptide toxicity. Proc. Natl. Acad. Sci. USA. 106:9191-9196.
32. Reference deleted in proof.
33. Hong, H. S., I. Maezawa, L. W. Jin. 2008. Candidate anti-Ab fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol. Aging. 31:1690-1699.
34. Tomaselli, S., V. Esposito, D. Picone. 2006. The α-to-β conformational transition of Alzheimer's Aβ-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of β conformation seeding. ChemBioChem. 7:257-267. (Pubitemid 43220939)
35. Lambert, M. P., A. K. Barlow, W. L. Klein. 1998. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:6448-6453.
36. Mastrangelo, I. A., M. Ahmed, S. O. Smith. 2006. High-resolution atomic force microscopy of soluble Aβ42 oligomers. J. Mol. Biol. 358:106-119.
37. Case, D. A., T. E. Cheatham, 3rd, R. J. Woods. 2005. The Amber biomolecular simulation programs. J. Comput. Chem. 26:1668-1688. (Pubitemid 43076180)
38. Duan, Y., C. Wu, P. Kollman. 2003. A point-charge force field for molecular mechanics simulations of proteins based on condensedphase quantum mechanical calculations. J. Comput. Chem. 24:1999-2012.
39. Wang, J. M., R. M. Wolf, D. A. Case. 2004. Development and testing of a general Amber force field. J. Comput. Chem. 25:1157-1174.
40. Dennington II, R., T. Keith, R. Gilliland. 2003. GaussView, Version 3.09. Semichem Inc., Shawnee Mission, KS.
41. Essmann, U., L. Perera, L. G. Pedersen. 1995. A smooth particle mesh Ewald method. J. Chem. Phys. 103:8577-8593.
42. Jorgensen, W. L., J. Chandrasekhar, M. L. Klein. 1983. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79:926-935.
43. Case, D. A., T. A. Darden, P. A. Kollman. 2004. AMBER 8. University of California, San Francisco.
44. Ryckaert, J. P., G. Ciccotti, and H. J. C. Berendsen. 1977. Numericalintegration of Cartesian equations of motion of a system with constraints-molecular-dynamics of N-alkanes. J. Comput. Phys. 23:327-341.
45. Andersen, H. C. 1980. Molecular-dynamics simulations at constant pressure and/or temperature. J. Chem. Phys. 72:2384-2393.
46. Chiu, S. W., M. Clark, E. Jakobsson. 2000. Collective motion artifacts arising in long-duration molecular dynamics simulations. J. Comput. Chem. 21:121-131.
47. Harvey, S. C., R. K. Z. Tan, and T. E. Cheatham. 1998. The flying ice cube: velocity rescaling in molecular dynamics leads to violation of energy equipartition. J. Comput. Chem. 19:726-740.
48. Kollman, P. A., I. Massova, T. E. Cheatham, 3rd. 2000. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33:889-897. (Pubitemid 32056774)